Lucid Diagnostics Inc. (LUCD) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US54948X1090

Price
0.43 USD
Market cap
87.86 m USD
P/E (2025)
–
P/S (2025)
18.67
Dividend yield
0.00 %
Net margin
-1,232.68 %
Return on equity (ROE)
-530.45 %
Return on assets (ROA)
-143.43 %

Lucid Diagnostics Inc. financials

Fiscal year20242025
Revenue4.35 m USD4.71 m USD
Gross profit-2.75 m USD-1.96 m USD
Operating income-46.05 m USD-49.64 m USD
EBIT-45.50 m USD-58.37 m USD
Net income-45.53 m USD-58.01 m USD
Diluted EPS – continuing operations-1.05 USD–

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.